Shopping Cart
Remove All
Your shopping cart is currently empty
diABZI STING agonist-1 (Tautomerism)
(Synonyms: diABZI STING agonist (Compound 3)) Copy Product Info
🥰Excellent
Synonyms: diABZI STING agonist (Compound 3)
Catalog No. T11035 Copy Product Info
Purity: 99.72%
🥰Excellent
diABZI STING agonist-1 (Tautomerism) (diABZI STING agonist (Compound 3)) is a selective agonist of the interferon gene-stimulated receptor (STING), with EC50 values of 130 nM in humans and 186 nM in mice. diABZI STING agonist-1 tautomerism is a tautomer of diABZI STING agonist-1. diABZI STING agonist-1 tautomerism can be used in research on tumor immunity, antiviral activity, and autoimmune diseases.
Cas No. 2138498-18-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $148 | In Stock | In Stock | |
| 2 mg | $218 | In Stock | In Stock | |
| 5 mg | $372 | In Stock | In Stock | |
| 10 mg | $533 | In Stock | In Stock | |
| 25 mg | $786 | In Stock | In Stock | |
| 50 mg | $1,080 | In Stock | In Stock | |
| 100 mg | $1,460 | - | In Stock | |
| 200 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.72%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | diABZI STING agonist-1 (Tautomerism) (diABZI STING agonist (Compound 3)) is a selective agonist of the interferon gene-stimulated receptor (STING), with EC50 values of 130 nM in humans and 186 nM in mice. diABZI STING agonist-1 tautomerism is a tautomer of diABZI STING agonist-1. diABZI STING agonist-1 tautomerism can be used in research on tumor immunity, antiviral activity, and autoimmune diseases. |
| Targets & IC50 | STNG (human, PBMC cells):130 nM (EC50), H69AR cells:0.035 μM (EC50), STNG (mouse):186 nM (EC50), H69AR cells:0.055 μM (EC50) |
| In vitro | Methods: Add 0–10 μM diABZI STING agonist-1 (Tautomerism) to THP-1 cells, treat for 2–4 h, and detect pSTING and pIRF3 expression by Western blot. Results: Treatment with diABZI STING agonist-1 (Tautomerism) upregulates pSTING and pIRF3 expression. [1] |
| In vivo | Methods: To investigate the anticancer effects of diABZI STING agonist-1 (Tautomerism), a BALB/c mouse CT-26 colon cancer model was established. Following successful inoculation, diABZI STING agonist-1 (Tautomerism) was administered intravenously at 30 μg/mouse on days 0, 3, and 6. Results: Treatment with diABZI STING agonist-1 (Tautomerism) resulted in significant tumor suppression, with complete regression observed in some mice, persisting more than for 60 days. [1] |
| Synonyms | diABZI STING agonist (Compound 3) |
| Molecular Weight | 849.94 |
| Formula | C42H51N13O7 |
| Cas No. | 2138498-18-5 |
| Smiles | C(/C=C/CN1C=2C(N=C1NC(=O)C=3N(CC)N=C(C)C3)=CC(C(N)=O)=CC2OC)N4C=5C(N=C4NC(=O)C=6N(CC)N=C(C)C6)=CC(C(N)=O)=CC5OCCCN7CCOCC7 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | Store at low temperature,Keep away from direct sunlight,The compound is unstable in solution. Please use soon Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (117.66 mM), Sonication is recommended. (The compound is unstable in solution, please use soon.)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: diABZI STING agonist-1 (Tautomerism) chemical structure | diABZI STING agonist-1 (Tautomerism) in vivo | diABZI STING agonist-1 (Tautomerism) in vitro | diABZI STING agonist-1 (Tautomerism) formula | diABZI STING agonist-1 (Tautomerism) molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.